日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Inhibition of METTL14 overcomes CDK4/6 inhibitor resistance driven by METTL14-m6A-E2F1-axis in ERα-positive breast cancer

抑制 METTL14 可克服 ERα 阳性乳腺癌中 METTL14-m6A-E2F1 轴驱动的 CDK4/6 抑制剂耐药性

Chenlin Liu #, Dong Fan #, Jiahui Sun #, Guodong Li #, Ruoxin Du, Xiaoshuang Zuo, Kuo Zhang, Wangqian Zhang, Shuning Wang, Xiaojv Li, Mingrui Du, Donghui Wang, Qiang Hao, Yingqi Zhang, Meng Li, Cun Zhang, Yuan Gao

NK cell immunopotentiators-loaded nanoliposomes enhance ADCC effect for targeted therapy against HER2-positive breast cancer

负载NK细胞免疫增强剂的纳米脂质体可增强ADCC效应,用于靶向治疗HER2阳性乳腺癌

Ruoxin Du # ,Changqing Cao # ,Dong Fan # ,Guodong Li ,Shuangpeng Pu ,Xinyao Xu ,Mengmeng Liu ,Gege Shi ,Yuxin Wu ,Qiang Hao ,Yuan Gao ,Juliang Zhang ,Huadong Zhao ,Cun Zhang

CD63+ cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20

CD63+ 癌症相关成纤维细胞通过外泌体 miR-20 赋予乳腺癌细胞 CDK4/6 抑制剂抗性

Jiahui Sun, Ruoxin Du, Xiaoju Li, Chenlin Liu, Donghui Wang, Xiangmei He, Guodong Li, Kuo Zhang, Shuning Wang, Qiang Hao, Yingqi Zhang, Meng Li, Yuan Gao, Cun Zhang

PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity

PDPN 阳性 CAF 通过抑制抗体依赖性 NK 细胞介导的细胞毒性,导致 HER2 阳性乳腺癌对曲妥珠单抗产生耐药性

Ruoxin Du, Xiangmei Zhang, Xiyan Lu, Xiangmin Ma, Xinyan Guo, Chao Shi, Xiaofei Ren, Xindi Ma, Yutong He, Yuan Gao, Yunjiang Liu

Epitranscriptomic editing of the RNA N6-methyladenosine modification by dCasRx conjugated methyltransferase and demethylase

dCasRx偶联的甲基转移酶和去甲基酶对RNA N6-甲基腺苷修饰进行表观转录组编辑

Zhen Xia ,Min Tang ,Jiayan Ma ,Hongyan Zhang ,Ryan C Gimple ,Briana C Prager ,Hongzhen Tang ,Chongran Sun ,Fuyi Liu ,Peng Lin ,Yutang Mei ,Ruoxin Du ,Jeremy N Rich ,Qi Xie